nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.03.2017 | Neuroimaging (DJ Brooks, Section Editor)

Neuroinflammation in Neurodegenerative Disorders—a Review

verfasst von: Martin Schain, William Charles Kreisl

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

The potential for positron emission tomography (PET) to detect neuroinflammation in vivo has sparked a remarkable interest in various disciplines of neuroscience. Early PET radioligands, such as [¹¹C]PK(R)-11195 for the 18-kDa translocator protein (TSPO) and [¹¹C]L-deprenyl for monoamine oxidase B, have been used in studies designed to clarify the role of neuroinflammation in a variety of psychiatric and neurological disorders. Recent years have witnessed the development of several second-generation PET radioligands for TSPO and radioligands to measure endogenous targets that are active in various stages of the inflammatory cascade, such as cyclooxygenase and arachidonic acid. Here, we discuss some of the biomarkers for neuroinflammation that are available for quantification with PET, as well as recent findings from studies where neuroinflammation has been assessed in neurodegenerative disorders. In addition, we highlight the challenges to accurate interpretation of PET studies of neuroinflammation.

Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, et al. In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. Brain Behav Immun. 2016;54:149–57. doi:10.1016/j.bbi.2016.01.019.PubMedCrossRef

Moses WW. Fundamental limits of spatial resolution in PET. Nucl Instrum Methods Phys Res A. 2011;648(Supplement 1):S236–S40. doi:10.1016/j.nima.2010.11.092.PubMedCrossRef

Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol. 2001;28(5):595–608.PubMedCrossRef

Varnas K, Varrone A, Farde L. Modeling of PET data in CNS drug discovery and development. J Pharmacokinet Pharmacodyn. 2013;40(3):267–79. doi:10.1007/s10928-013-9320-6.PubMedCrossRef

Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3 Pt 1):153–8. doi:10.1006/nimg.1996.0066.PubMedCrossRef

Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834–40. doi:10.1097/00004647-199609000-00008.PubMedCrossRef

Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35(12):2304–19. doi:10.1007/s00259-008-0908-9.PubMedCrossRef

Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci U S A. 1977;74(9):3805–9.PubMedPubMedCentralCrossRef

Papadopoulos V, Aghazadeh Y, Fan J, Campioli E, Zirkin B, Midzak A. Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesis. Mol Cell Endocrinol. 2015;408:90–8. doi:10.1016/j.mce.2015.03.014.PubMedPubMedCentralCrossRef

10.

Papadopoulos V, Miller WL. Role of mitochondria in steroidogenesis. Best Pract Res Clin Endocrinol Metab. 2012;26(6):771–90. doi:10.1016/j.beem.2012.05.002.PubMedCrossRef

11.

Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27(8):402–9. doi:10.1016/j.tips.2006.06.005.PubMedCrossRef

12.

Banati RB, Middleton RJ, Chan R, Hatty CR, Kam WW, Quin C, et al. Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat Commun. 2014;5:5452. doi:10.1038/ncomms6452.PubMedPubMedCentralCrossRef

13.

Morohaku K, Pelton SH, Daugherty DJ, Butler WR, Deng W, Selvaraj V. Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology. 2014;155(1):89–97. doi:10.1210/en.2013-1556.PubMedCrossRef

14.

Selvaraj V, Stocco DM, Tu LN. Translocator protein (TSPO) and steroidogenesis: a reappraisal. Mol Endocrinol. 2015;29(4):490–501. doi:10.1210/me.2015-1033.PubMedPubMedCentralCrossRef

15.

Tu LN, Morohaku K, Manna PR, Pelton SH, Butler WR, Stocco DM, et al. Peripheral benzodiazepine receptor/translocator protein global knock-out mice are viable with no effects on steroid hormone biosynthesis. J Biol Chem. 2014;289(40):27444–54. doi:10.1074/jbc.M114.578286.PubMedPubMedCentralCrossRef

16.

Tu LN, Zhao AH, Stocco DM, Selvaraj V. PK11195 effect on steroidogenesis is not mediated through the translocator protein (TSPO). Endocrinology. 2015;156(3):1033–9. doi:10.1210/en.2014-1707.PubMedCrossRef

17.

Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int. 2002;40(6):475–86.PubMedCrossRef

18.

Kuhlmann AC, Guilarte TR. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem. 2000;74(4):1694–704.PubMedCrossRef

19.

Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35(3):306–28. doi:10.1111/j.1365-2990.2008.01006.x.PubMedCrossRef

20.

Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62(1):15–30.PubMedCrossRef

21.

Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7(12):e52941. doi:10.1371/journal.pone.0052941.PubMedPubMedCentralCrossRef

22.

Saura J, Richards JG, Mahy N. Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol Aging. 1994;15(4):399–408.PubMedCrossRef

23.

Saura J, Richards JG, Mahy N. Age-related changes on MAO in Bl/C57 mouse tissues: a quantitative radioautographic study. J Neural Transm Suppl. 1994;41:89–94.PubMed

24.

Aquilonius SM, Jossan SS, Ekblom JG, Askmark H, Gillberg PG. Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography. J Neural Transm Gen Sect. 1992;89(1–2):111–22.PubMedCrossRef

25.

Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer’s disease: a biochemical and autoradiographical study. Neuroscience. 1991;45(1):1–12.PubMedCrossRef

26.

Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol. 1990;80(4):419–25.PubMedCrossRef

27.

Oreland L. Monoamine oxidase activity and affective illness. Acta Psychiatr Scand Suppl. 1980;280:41–7.PubMed

28.

Aid S, Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie. 2011;93(1):46–51. doi:10.1016/j.biochi.2010.09.009.PubMedCrossRef

29.

Le Fur G, Vaucher N, Perrier ML, Flamier A, Benavides J, Renault C, et al. Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci. 1983;33(5):449–57.PubMedCrossRef

30.

Guo Y, Kalathur RC, Liu Q, Kloss B, Bruni R, Ginter C, et al. Protein structure. Structure and activity of tryptophan-rich TSPO proteins. Science. 2015;347(6221):551–5. doi:10.1126/science.aaa1534.PubMedPubMedCentralCrossRef

31.

Diorio D, Welner SA, Butterworth RF, Meaney MJ, Suranyi-Cadotte BE. Peripheral benzodiazepine binding sites in Alzheimer’s disease frontal and temporal cortex. Neurobiol Aging. 1991;12(3):255–8.PubMedCrossRef

32.

Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, et al. PK11195 labels activated microglia in Alzheimer’s disease and in vivo in a mouse model using PET. Neurobiol Aging. 2009;30(8):1217–26. doi:10.1016/j.neurobiolaging.2007.11.005.PubMedCrossRef

33.

Hatty CR, Le Brun AP, Lake V, Clifton LA, Liu GJ, James M, et al. Investigating the interactions of the 18 kDa translocator protein and its ligand PK11195 in planar lipid bilayers. Biochim Biophys Acta. 2014;1838(3):1019–30. doi:10.1016/j.bbamem.2013.12.013.PubMedCrossRef

34.

Lockhart A, Davis B, Matthews JC, Rahmoune H, Hong G, Gee A, et al. The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant alpha1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker. Nucl Med Biol. 2003;30(2):199–206.PubMedCrossRef

35.

Kreisl WC, Fujita M, Fujimura Y, Kimura N, Jenko KJ, Kannan P, et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage. 2010;49(4):2924–32. doi:10.1016/j.neuroimage.2009.11.056.PubMedCrossRef

36.

Albrecht DS, Granziera C, Hooker JM, Loggia ML. In vivo imaging of human neuroinflammation. ACS Chem Neurosci. 2016;7(4):470–83. doi:10.1021/acschemneuro.6b00056.PubMedCrossRef

37.

Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52(1):24–32. doi:10.2967/jnumed.110.079459.PubMedCrossRef

38.

Owen DR, Howell OW, Tang SP, Wells LA, Bennacef I, Bergstrom M, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30(9):1608–18. doi:10.1038/jcbfm.2010.63.PubMedPubMedCentralCrossRef

39.

Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1–5. doi:10.1038/jcbfm.2011.147.PubMedCrossRef

40.

Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab. 2013;33(1):53–8. doi:10.1038/jcbfm.2012.131.PubMedCrossRef

41.

Herrera Rivero M, Heneka MT, Papadopoulos V. Translocator protein and new targets for neuroinflammation. Clin Transl Imaging. 2015;3(6):391–402. doi:10.1007/s40336-015-0151-x.CrossRef

42.

Fowler JS, Logan J, Shumay E, Alia-Klein N, Wang GJ, Volkow ND. Monoamine oxidase: radiotracer chemistry and human studies. J Labelled Comp Radiopharm. 2015;58(3):51–64. doi:10.1002/jlcr.3247.PubMedCrossRef

43.

Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science. 1987;235(4787):481–5.PubMedCrossRef

44.

Fowler JS, Logan J, Wang GJ, Volkow ND, Telang F, Ding YS, et al. Comparison of the binding of the irreversible monoamine oxidase tracers, [(11)C]clorgyline and [(11)C]l-deprenyl in brain and peripheral organs in humans. Nucl Med Biol. 2004;31(3):313–9. doi:10.1016/j.nucmedbio.2003.10.003.PubMedCrossRef

45.

Nag S, Lehmann L, Kettschau G, Toth M, Heinrich T, Thiele A, et al. Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). Bioorg Med Chem. 2013;21(21):6634–41. doi:10.1016/j.bmc.2013.08.019.PubMedCrossRef

46.

Nag S, Kettschau G, Heinrich T, Varrone A, Lehmann L, Gulyas B, et al. Synthesis and biological evaluation of novel propargyl amines as potential fluorine-18 labeled radioligands for detection of MAO-B activity. Bioorg Med Chem. 2013;21(1):186–95. doi:10.1016/j.bmc.2012.10.050.PubMedCrossRef

47.

Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med. 1995;36(7):1255–62.PubMed

48.

Chang MC, Arai T, Freed LM, Wakabayashi S, Channing MA, Dunn BB, et al. Brain incorporation of [1-11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. Brain Res. 1997;755(1):74–83.PubMedCrossRef

49.

Giovacchini G, Chang MC, Channing MA, Toczek M, Mason A, Bokde AL, et al. Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography. J Cereb Blood Flow Metab. 2002;22(12):1453–62. doi:10.1097/00004647-200212000-00006.PubMedCrossRef

50.

Esposito G, Giovacchini G, Der M, Liow JS, Bhattacharjee AK, Ma K, et al. Imaging signal transduction via arachidonic acid in the human brain during visual stimulation, by means of positron emission tomography. Neuroimage. 2007;34(4):1342–51. doi:10.1016/j.neuroimage.2006.11.018.PubMedCrossRef

51.

Takashima-Hirano M, Shukuri M, Takashima T, Goto M, Wada Y, Watanabe Y, et al. General method for the (11)C-labeling of 2-arylpropionic acids and their esters: construction of a PET tracer library for a study of biological events involved in COXs expression. Chemistry. 2010;16(14):4250–8. doi:10.1002/chem.200903044.PubMedCrossRef

52.

Shukuri M, Takashima-Hirano M, Tokuda K, Takashima T, Matsumura K, Inoue O, et al. In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl ester. J Nucl Med. 2011;52(7):1094–101. doi:10.2967/jnumed.110.084046.PubMedCrossRef

53.

Shukuri M, Mawatari A, Ohno M, Suzuki M, Doi H, Watanabe Y, et al. Detection of cyclooxygenase-1 in activated microglia during amyloid plaque progression: PET studies in Alzheimer’s disease model mice. J Nucl Med. 2016;57(2):291–6. doi:10.2967/jnumed.115.166116.PubMedCrossRef

54.

Ohnishi A, Senda M, Yamane T, Sasaki M, Mikami T, Nishio T, et al. Human whole-body biodistribution and dosimetry of a new PET tracer, [(11)C]ketoprofen methyl ester, for imagings of neuroinflammation. Nucl Med Biol. 2014;41(7):594–9. doi:10.1016/j.nucmedbio.2014.04.008.PubMedCrossRef

55.

Ohnishi A, Senda M, Yamane T, Mikami T, Nishida H, Nishio T, et al. Exploratory human PET study of the effectiveness of (11)C-ketoprofen methyl ester, a potential biomarker of neuroinflammatory processes in Alzheimer’s disease. Nucl Med Biol. 2016;43(7):438–44. doi:10.1016/j.nucmedbio.2016.04.005.PubMedCrossRef

56.

Ji B, Kumata K, Onoe H, Kaneko H, Zhang MR, Seki C, et al. Assessment of radioligands for PET imaging of cyclooxygenase-2 in an ischemic neuronal injury model. Brain Res. 2013;1533:152–62. doi:10.1016/j.brainres.2013.08.026.PubMedCrossRef

57.

Pacelli A, Greenman J, Cawthorne C, Smith G. Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions. J Labelled Comp Radiopharm. 2014;57(4):317–22. doi:10.1002/jlcr.3160.PubMedCrossRef

58.

Tietz O, Wuest M, Marshall A, Glubrecht D, Hamann I, Wang M, et al. PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model. EJNMMI Res. 2016;6(1):37. doi:10.1186/s13550-016-0192-9.PubMedPubMedCentralCrossRef

59.

Baik SH, Kang S, Son SM, Mook-Jung I. Microglia contributes to plaque growth by cell death due to uptake of amyloid beta in the brain of Alzheimer’s disease mouse model. Glia. 2016;64(12):2274–90. doi:10.1002/glia.23074.PubMedCrossRef

60.

Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D, et al. TREM2 is associated with increased risk for Alzheimer’s disease in African Americans. Mol Neurodegener. 2015;10:19. doi:10.1186/s13024-015-0016-9.PubMedPubMedCentralCrossRef

61.

Lee M, McGeer E, McGeer PL. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer’s disease pathogenesis. Neurobiol Aging. 2015;36(1):42–52. doi:10.1016/j.neurobiolaging.2014.07.024.PubMedCrossRef

62.

McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126(4):479–97. doi:10.1007/s00401-013-1177-7.PubMedCrossRef

63.

Raha AA, Henderson JW, Stott SR, Vuono R, Foscarin S, Friedland RP, et al. Neuroprotective effect of TREM-2 in aging and Alzheimer’s disease model. J Alzheimers Dis. 2016. doi:10.3233/JAD-160663.

64.

Asai H, Ikezu S, Woodbury ME, Yonemoto GM, Cui L, Ikezu T. Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1. Am J Pathol. 2014;184(3):808–18. doi:10.1016/j.ajpath.2013.11.026.PubMedPubMedCentralCrossRef

65.

Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem. 2011;286(5):3693–706. doi:10.1074/jbc.M110.135244.PubMedCrossRef

66.

Marlatt MW, Bauer J, Aronica E, van Haastert ES, Hoozemans JJ, Joels M, et al. Proliferation in the Alzheimer hippocampus is due to microglia, not astroglia, and occurs at sites of amyloid deposition. Neural Plast. 2014;2014:693851. doi:10.1155/2014/693851.PubMedPubMedCentralCrossRef

67.

Morales I, Jimenez JM, Mancilla M, Maccioni RB. Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis. 2013;37(4):849–56. doi:10.3233/JAD-131843.PubMed

68.

Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R, et al. Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neurosci Lett. 2001;305(3):165–8.PubMedCrossRef

69.

Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358(9280):461–7. doi:10.1016/S0140-6736(01)05625-2.PubMedCrossRef

70.

Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32(3):412–9. doi:10.1016/j.nbd.2008.08.001.PubMedCrossRef

71.

Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38(2):343–51. doi:10.1007/s00259-010-1612-0.PubMedCrossRef

72.

Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72(1):56–62. doi:10.1212/01.wnl.0000338622.27876.0d.PubMedPubMedCentralCrossRef

73.

• Fan Z, Okello AA, Brooks DJ, Edison P. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease. Brain. 2015;138(Pt 12):3685–98. doi:10.1093/brain/awv288. The first published longitudinal study to show that TSPO binding on PET increases over time in patients with Alzheimer’s disease.PubMedCrossRef

74.

Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer’s disease. J Nucl Med. 1995;36(12):2207–10.PubMed

75.

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66(1):60–7. doi:10.1001/archneurol.2008.511.PubMedPubMedCentralCrossRef

76.

Schuitemaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF, et al. Microglial activation in Alzheimer’s disease: an (R)-[(11)C]PK11195 positron emission tomography study. Neurobiol Aging. 2013;34(1):128–36. doi:10.1016/j.neurobiolaging.2012.04.021.PubMedCrossRef

77.

Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain. 2013;136(Pt 7):2228–38. doi:10.1093/brain/awt145.PubMedPubMedCentralCrossRef

78.

• Lyoo CH, Ikawa M, Liow JS, Zoghbi SS, Morse C, Pike VW, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer’s disease to detect neuroinflammation measured with PET radioligand binding to translocator protein (TSPO). J Nucl Med. 2015. doi:10.2967/jnumed.114.146027. This paper validated a reference region method in the second generation radioligand [ ¹¹ C]PBR28 to avoid use of arterial catheterization in PET studies of patients with Alzheimer’s disease.

79.

Maeda J, Zhang MR, Okauchi T, Ji B, Ono M, Hattori S, et al. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer’s disease and related disorders. Australas J Neurosci. 2011;31(12):4720–30. doi:10.1523/JNEUROSCI.3076-10.2011.CrossRef

80.

Gulyas B, Makkai B, Kasa P, Gulya K, Bakota L, Varszegi S, et al. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem Int. 2009;54(1):28–36. doi:10.1016/j.neuint.2008.10.001.PubMedCrossRef

81.

Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. 2008;64(10):835–41. doi:10.1016/j.biopsych.2008.04.021.PubMedCrossRef

82.

Yasuno F, Kosaka J, Ota M, Higuchi M, Ito H, Fujimura Y, et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [(11)C]DAA1106. Psychiatry Res. 2012;203(1):67–74. doi:10.1016/j.pscychresns.2011.08.013.PubMedCrossRef

83.

Varrone A, Mattsson P, Forsberg A, Takano A, Nag S, Gulyas B, et al. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients. Eur J Nucl Med Mol Imaging. 2013;40(6):921–31. doi:10.1007/s00259-013-2359-1.PubMedCrossRef

84.

Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E, et al. (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease. Neurobiol Aging. 2016;44:53–61. doi:10.1016/j.neurobiolaging.2016.04.011.PubMedCrossRef

85.

Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139(Pt 4):1252–64. doi:10.1093/brain/aww017.PubMedCrossRef

86.

Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53(1):37–46. doi:10.2967/jnumed.110.087031.PubMedCrossRef

87.

Santillo AF, Gambini JP, Lannfelt L, Langstrom B, Ulla-Marja L, Kilander L, et al. In vivo imaging of astrocytosis in Alzheimer’s disease: an (11)C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging. 2011;38(12):2202–8. doi:10.1007/s00259-011-1895-9.PubMedCrossRef

88.

Hirvonen J, Kailajarvi M, Haltia T, Koskimies S, Nagren K, Virsu P, et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009;85(5):506–12. doi:10.1038/clpt.2008.241.PubMedCrossRef

89.

Choo IL, Carter SF, Scholl ML, Nordberg A. Astrocytosis measured by (11)C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients. Eur J Nucl Med Mol Imaging. 2014;41(11):2120–6. doi:10.1007/s00259-014-2859-7.PubMedCrossRef

90.

Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, et al. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3510-6.PubMedPubMedCentral

91.

Esposito G, Giovacchini G, Liow JS, Bhattacharjee AK, Greenstein D, Schapiro M, et al. Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET. J Nucl Med. 2008;49(9):1414–21. doi:10.2967/jnumed.107.049619.PubMedPubMedCentralCrossRef

92.

Ohama E, Ikuta F. Parkinson’s disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol. 1976;34(4):311–9.PubMedCrossRef

93.

McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(3 Suppl):417–23.PubMed

94.

Brettschneider J, Irwin DJ, Boluda S, Byrne MD, Fang L, Lee EB, et al. Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. Neuropathol Appl Neurobiol. 2016. doi:10.1111/nan.12362.PubMed

95.

Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett. 1998;251(3):205–8.PubMedCrossRef

96.

Taguchi K, Watanabe Y, Tsujimura A, Tanaka M. Brain region-dependent differential expression of alpha-synuclein. J Comp Neurol. 2016;524(6):1236–58. doi:10.1002/cne.23901.PubMedCrossRef

97.

Sone M, Yoshida M, Hashizume Y, Hishikawa N, Sobue G. alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta Neuropathol. 2005;110(1):19–26. doi:10.1007/s00401-005-1013-9.PubMedCrossRef

98.

Lebouvier T, Neunlist M, Bruley des Varannes S, Coron E, Drouard A, N’Guyen JM, et al. Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS One. 2010;5(9):e12728. doi:10.1371/journal.pone.0012728.PubMedPubMedCentralCrossRef

99.

Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21(2):404–12. doi:10.1016/j.nbd.2005.08.002.PubMedCrossRef

100.

Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, et al. Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology. 2013;38(6):938–49. doi:10.1038/npp.2012.255.PubMedPubMedCentralCrossRef

101.

Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S, et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(1):47–52. doi:10.1016/j.parkreldis.2012.07.002.PubMedCrossRef

102.

Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003;61(5):686–9.PubMedCrossRef

103.

Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25(1):97–107. doi:10.1002/mds.22732.PubMedCrossRef

104.

• Jucaite A, Svenningsson P, Rinne JO, Cselenyi Z, Varnas K, Johnstrom P, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease. Brain. 2015;138(Pt 9):2687–700. doi:10.1093/brain/awv184. The authors demonstrated that TSPO binding can be reduced in patients with Parkinson’s disease using a novel myeloperoxidase inhibitor.PubMedCrossRef

105.

Koshimori Y, Ko JH, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF, et al. Imaging striatal microglial activation in patients with Parkinson’s disease. PLoS One. 2015;10(9):e0138721. doi:10.1371/journal.pone.0138721.PubMedPubMedCentralCrossRef

106.

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry. 1994;57(4):416–8.

107.

Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol. 2014;13(7):686–99. doi:10.1016/S1474-4422(14)70065-1.PubMedPubMedCentralCrossRef

108.

Ferrer I, Lopez-Gonzalez I, Carmona M, Arregui L, Dalfo E, Torrejon-Escribano B, et al. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J Neuropathol Exp Neurol. 2014;73(1):81–97. doi:10.1097/NEN.0000000000000030.PubMedCrossRef

109.

Laws SM, Friedrich P, Diehl-Schmid J, Muller J, Ibach B, Bauml J, et al. Genetic analysis of MAPT haplotype diversity in frontotemporal dementia. Neurobiol Aging. 2008;29(8):1276–8. doi:10.1016/j.neurobiolaging.2007.02.019.PubMedCrossRef

110.

Lindquist SG, Schwartz M, Batbayli M, Waldemar G, Nielsen JE. Genetic testing in familial AD and FTD: mutation and phenotype spectrum in a Danish cohort. Clin Genet. 2009;76(2):205–9. doi:10.1111/j.1399-0004.2009.01191.x.PubMedCrossRef

111.

Caroppo P, Camuzat A, Guillot-Noel L, Thomas-Anterion C, Couratier P, Wong TH, et al. Defining the spectrum of frontotemporal dementias associated with TARDBP mutations. Neurol Genet. 2016;2(3):e80. doi:10.1212/NXG.0000000000000080.PubMedPubMedCentralCrossRef

112.

He F, Jones JM, Figueroa-Romero C, Zhang D, Feldman EL, Goutman SA, et al. Screening for novel hexanucleotide repeat expansions at ALS- and FTD-associated loci. Neurol Genet. 2016;2(3):e71. doi:10.1212/NXG.0000000000000071.PubMedPubMedCentralCrossRef

113.

Lee EB, Russ J, Jung H, Elman LB, Chahine LM, Kremens D, et al. Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U. Acta Neuropathol Commun. 2013;1(9):1–11. doi:10.1186/2051-5960-1-9.PubMed

114.

Ioannidis P, Konstantinopoulou E, Maiovis P, Karacostas D. The frontotemporal dementias in a tertiary referral center: classification and demographic characteristics in a series of 232 cases. J Neurol Sci. 2012;318(1–2):171–3. doi:10.1016/j.jns.2012.04.002.PubMedCrossRef

115.

Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004;56(6):894–7. doi:10.1002/ana.20332.PubMedCrossRef

116.

Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord. 2004;19(10):1221–6. doi:10.1002/mds.20162.PubMedCrossRef

117.

Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. 2006;21(1):89–93. doi:10.1002/mds.20668.PubMedCrossRef

118.

Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61(11):935–46.PubMedCrossRef

119.

Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Imaging microglial activation in Huntington’s disease. Brain Res Bull. 2007;72(2–3):148–51. doi:10.1016/j.brainresbull.2006.10.029.PubMedCrossRef

120.

Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001;60(2):161–72.PubMedCrossRef

121.

Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 2006;66(11):1638–43. doi:10.1212/01.wnl.0000222734.56412.17.PubMedCrossRef

122.

Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain. 2007;130(Pt 7):1759–66. doi:10.1093/brain/awm044.PubMedCrossRef

123.

Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington’s disease: an in vivo PET study. Brain. 2008;131(Pt 11):2860–9. doi:10.1093/brain/awn244.PubMedCrossRef

124.

Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp. 2011;32(2):258–70. doi:10.1002/hbm.21008.PubMedCrossRef

125.

Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol. 2011;30(1):4–8.PubMedPubMedCentral

126.

Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601–9. doi:10.1016/j.nbd.2003.12.012.PubMedCrossRef

127.

Sitte HH, Wanschitz J, Budka H, Berger ML. Autoradiography with [3H]PK11195 of spinal tract degeneration in amyotrophic lateral sclerosis. Acta Neuropathol. 2001;101(2):75–8.PubMed

128.

Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. NeuroImage Clinical. 2015;7:409–14. doi:10.1016/j.nicl.2015.01.009.PubMedPubMedCentralCrossRef

Titel: Neuroinflammation in Neurodegenerative Disorders—a Review
verfasst von: Martin Schain
William Charles Kreisl
Publikationsdatum: 01.03.2017
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 3/2017
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-017-0733-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

PFO and Migraine: Is There a Role for Closure?

Update on the Genetics of Dystonia

Migraine and Stroke: What’s the Link? What to Do?

Recurrent Gastrointestinal Disturbance: Abdominal Migraine and Cyclic Vomiting Syndrome

Integrating the Constructs of Anosognosia and Metacognition: a Review of Recent Findings in Dementia